08043420100
What are the treatment options for prostate cancer?
Prostate cancer treatment is tailored to each patient and includes: Robotic Radical Prostatectomy – Minimally invasive robotic-assisted removal of the prostate. Radiation Therapy (IMRT, SBRT, Brachytherapy) – Targeted radiation to destroy cancer cells. HIFU (High-Intensity Focused Ultrasound) & TULSA (Transurethral Ultrasound Ablation) – Non-invasive treatments that use ultrasound energy to destroy cancerous tissue while preserving healthy structures. Hormone Therapy & Immunotherapy – Used for advanced cases or as adjuvant treatment.
Is robotic surgery better than traditional surgery for prostate cancer?
Yes, robotic-assisted radical prostatectomy offers several advantages over open surgery, including: Enhanced precision in tumor removal while preserving nerves responsible for continence and sexual function. Minimally invasive approach leading to less pain, quicker recovery, and shorter hospital stay. Reduced risk of complications such as blood loss, infection, and long-term side effects.
What is robotic-assisted surgery, and how does it benefit urological cancer treatment?
Robotic-assisted surgery uses minimally invasive robotic technology to perform high-precision cancer surgeries with smaller incisions, less blood loss, reduced pain, shorter hospital stays, and faster recovery compared to traditional open surgery. The 4th Generation Da Vinci Surgical System and SSI Mantra Robot used at Aster offer tremor-free, 3D magnified vision, allowing surgeons to precisely remove tumors while preserving vital structures like nerves and blood vessels.
What are the most common urological cancers?
The most frequently treated cancers in Uro-Oncology include: Prostate Cancer – The most common urological cancer in men, often detected through PSA screening. Bladder Cancer – Characterized by blood in urine (hematuria) and often requiring surgery or intravesical therapy. Kidney Cancer – Includes renal cell carcinoma, usually detected incidentally via imaging. Testicular Cancer – Highly curable when detected early, typically affecting younger men. Penile Cancer – A rare but aggressive cancer requiring early diagnosis and treatment. Adrenal Tumors – Includes both benign and malignant adrenal gland tumors.
What is Uro-Oncology, and how is it different from general urology?
Uro-Oncology is a specialized branch of oncology focused on the diagnosis, treatment, and management of cancers affecting the prostate, bladder, kidney, testicles, penis, and adrenal glands. Unlike general urology, which treats a broad range of urinary tract conditions, Uro-Oncology specifically deals with urological malignancies and uses advanced techniques such as robotic-assisted surgery, targeted therapies, and precision imaging for better outcomes.
How can families access paediatric haematology and oncology services at AIIO?
Families can access our services by scheduling appointments through our website or contacting our hospital directly. Our team is dedicated to guiding families through the process and ensuring a smooth experience for paediatric patients.
Can parents actively participate in decision-making regarding their child's treatment plan?
Absolutely. We believe in a collaborative approach, and parents are encouraged to actively participate in the decision-making process for their child's treatment. Open communication is key to the success of our treatment plans.
What safety measures are in place for paediatric patients at AIIO's state-of-the-art facility?
AIIO prioritizes the safety of paediatric patients, adhering to the highest standards in healthcare. Our state-of-the-art facility is equipped with cutting-edge technology, ensuring optimal care in a secure environment.
How does the collaborative approach work in paediatric care at AIIO?
Our paediatric haematology, oncology, and stem cell transplant team collaborates seamlessly with surgeons, radiatuon oncologist nurses, and support staff. This collaborative model ensures comprehensive and coordinated care for each child.
Is AIIO involved in research initiatives for paediatric haematology and oncology?
Yes, AIIO is actively involved in clinical trials and research aimed at advancing paediatric haematology and oncology. We are committed to improving treatment outcomes and expanding our understanding of these conditions.